Pharma & Biotech
Bayer’s Fundamentals Swing Upward, but the 200-Day Line Remains a Battleground
Bayer delivered a first-quarter earnings report that should have been a catalyst for its stock. Adjusted earnings per share jumped...
BioNTech’s Bet on BNT323 Intensifies as Restructuring and Pipeline Data Pave Way for Regulatory Milestone
The next few months will decide whether BioNTech can turn its sprawling oncology pipeline into a revenue-generating reality. With a...
Ocugen’s Data-Driven Countdown: Three Parallel Catalysts Converge in Q3 2026
Ocugen’s stock has been on a rollercoaster, sliding 25% over the past month to trade at €1.18, but the company...
Eli Lilly’s Most Consequential Weekend: New Mounjaro Data Meets a $3.8 Billion Vaccine Pivot
Eli Lilly closed last week with a flurry of news that turned the stock into a tale of two catalysts....
Assembly Biosciences Strengthens Pipeline and Balance Sheet After $115M Upsized Raise
Assembly Biosciences has emerged from the EASL Congress in Barcelona with more than just data. The biotech firm capped a...
Eli Lilly’s Two-Front Victory: A Trillion-Dollar Valuation and a Pharmacy Benefit Win Reshape the Obesity Landscape
Eli Lilly has barrelled past a historic threshold, becoming the first pharmaceutical company to reach a market capitalisation of $1...
BioNTech’s $650 Million R&D Quarter: Shareholders Back Board Expansion as Market Awaits Lung Cancer Data
Despite sitting on nearly $20 billion in cash, BioNTech is burning through money at an accelerating pace as it races...
Ocugen’s Gene Therapy Candidates Race Toward FDA Filings, But the Market Isn’t Ready to Celebrate
Ocugen is making quiet but meaningful progress across its pipeline of gene therapy programmes, yet the stock tells a more...
Ocugen Locks In Cash Runway to 2028 as Gene Therapy Platform Heads to Fort Lauderdale and Beyond
Ocugen has closed a $115 million convertible note offering that buys the biotech group more than two years of operating...
BioNTech’s Radical Overhaul: 1,860 Job Cuts, Factory Shutdowns, and a €532 Million Loss as Cancer Bet Takes Center Stage
The era of pandemic-era blockbuster revenues at BioNTech has come to a definitive end. The Mainz-based biotech is shuttering four...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
